Cardinal Health Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Cardinal Health Inc trades at $240.4 (market cap $55.88B), while Vertex Pharmaceuticals Incorporated trades at $529.62 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.4× Cardinal Health Inc's market cap, and Cardinal Health Inc pays a 0.86% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| CAH | VRTX | |
|---|---|---|
Market Cap | $55.88B | $134.25B |
Sector | Health | Health |
52-Week High | $240.26 | $529.65 |
52-Week Low | $146.04 | $376.62 |
Enterprise Value | $59.91B | $128.37B |
Dividend Yield | 0.86% | — |
Trailing returns across standard periods
Latest headlines on both assets
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →